Receptor-Mediated Muscle Homeostasis as a Target for Sarcopenia Therapeutics

被引:10
作者
Yoon, Jong Hyeon [1 ,2 ]
Kwon, Ki-Sun [1 ,2 ,3 ]
机构
[1] Korea Res Inst Biosci & Biotechnol KRIBB, Aging Res Ctr, 125 Gwahak Ro, Daejeon 34141, South Korea
[2] Korea Univ Sci & Technol, Dept Funct Genom, KRIBB Sch Biosci, Daejeon, South Korea
[3] Aventi Inc, Daejeon, South Korea
基金
新加坡国家研究基金会;
关键词
Sarcopenia; Muscle; skeletal; Aging; Drug therapy; Receptors; cell surface; cytoplasmic and nuclear; Signal transduction; Molecular mechanisms of pharmacological action; Clinical trial; GROWTH-FACTOR-I; TESTOSTERONE REPLACEMENT THERAPY; ASIAN WORKING GROUP; PROOF-OF-CONCEPT; SKELETAL-MUSCLE; VITAMIN-D; MUSCULAR-DYSTROPHY; IGF-I; MESSENGER-RNA; DOUBLE-BLIND;
D O I
10.3803/EnM.2021.1081
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Salvopenia is a disease characterized by age-related decline of skeletal muscle mass and function. The molecular mechanisms of the pathophysiology of sarcopenia form a complex network due to the involvement of multiple interconnected signaling pathways. Therefore, signaling receptors are major targets in pharmacological strategies in general. To provide a rationale for pharmacological interventions for sarcopenia, we herein describe several druggable signaling receptors based on their role in skeletal muscle homeostasis and changes in their activity with aging. A brief overview is presented of the efficacy of corresponding drug candidates under clinical trials. Strategies targeting the androgen receptor, vitamin D receptor, Insulin-like growth factor-1 receptor, and ghrelin receptor primarily focus on promoting anabolic action using natural ligands or mimetics. Strategies involving activin receptors and angiotensin receptors focus on inhibiting catabolic action. This review may help to select specific targets or combinations of targets in the future.
引用
收藏
页码:478 / 490
页数:13
相关论文
共 119 条
  • [1] Molecular mechanisms of glucocorticosteroid actions
    Adcock, IM
    [J]. PULMONARY PHARMACOLOGY & THERAPEUTICS, 2000, 13 (03) : 115 - 126
  • [2] Protective Effect of Angiotensin 1-7 on Sarcopenia Induced by Chronic Liver Disease in Mice
    Aguirre, Francisco
    Abrigo, Johanna
    Gonzalez, Francisco
    Gonzalez, Andrea
    Simon, Felipe
    Cabello-Verrugio, Claudio
    [J]. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2020, 21 (11) : 1 - 16
  • [3] Sarcopenia, Cachexia and Aging: Diagnosis, Mechanisms and Therapeutic Options - A Mini-Review
    Ali, Sumbul
    Garcia, Jose M.
    [J]. GERONTOLOGY, 2014, 60 (04) : 294 - 305
  • [4] Down-Regulation of Akt/Mammalian Target of Rapamycin Signaling Pathway in Response to Myostatin Overexpression in Skeletal Muscle
    Amirouche, Adel
    Durieux, Anne-Cecile
    Banzet, Sebastien
    Koulmann, Nathalie
    Bonnefoy, Regis
    Mouret, Catherine
    Bigard, Xavier
    Peinnequin, Andre
    Freyssenet, Damien
    [J]. ENDOCRINOLOGY, 2009, 150 (01) : 286 - 294
  • [5] Use of growth hormone, IGF-I, and insulin for anabolic purpose: Pharmacological basis, methods of detection, and adverse effects
    Anderson, Lindsey J.
    Tamayose, Jamie M.
    Garcia, Jose M.
    [J]. MOLECULAR AND CELLULAR ENDOCRINOLOGY, 2018, 464 (0C) : 65 - 74
  • [6] Endocytic mechanisms for targeted drug delivery
    Bareford, Lisa A.
    Swaan, Peter W.
    [J]. ADVANCED DRUG DELIVERY REVIEWS, 2007, 59 (08) : 748 - 758
  • [7] Viral mediated expression of insulin-like growth factor I blocks the aging-related loss of skeletal muscle function
    Barton-Davis, ER
    Shoturma, DI
    Musaro, A
    Rosenthal, N
    Sweeney, HL
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (26) : 15603 - 15607
  • [8] The Effects of Vitamin D on Skeletal Muscle Strength, Muscle Mass, and Muscle Power: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
    Beaudart, Charlotte
    Buckinx, Fanny
    Rabenda, Veronique
    Gillain, Sophie
    Cavalier, Etienne
    Slomian, Justine
    Petermans, Jean
    Reginster, Jean-Yves
    Bruyere, Olivier
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2014, 99 (11) : 4336 - 4345
  • [9] Myostatin antibody (LY2495655) in older weak fallers: a proof-of-concept, randomised, phase 2 trial
    Becker, Clemens
    Lord, Stephen R.
    Studenski, Stephanie A.
    Warden, Stuart J.
    Fielding, Roger A.
    Recknor, Christopher P.
    Hochberg, Marc C.
    Ferrari, Serge L.
    Blain, Hubert
    Binder, Ellen F.
    Rolland, Yves
    Poiraudeau, Serge
    Benson, Charles T.
    Myers, Stephen L.
    Hu, Leijun
    Ahmad, Qasim I.
    Pacuch, Kelli R.
    Gomez, Elisa V.
    Benichou, Olivier
    [J]. LANCET DIABETES & ENDOCRINOLOGY, 2015, 3 (12) : 948 - 957
  • [10] Angiotensin II revisited: new roles in inflammation, immunology and aging
    Benigni, Ariela
    Cassis, Paola
    Remuzzi, Giuseppe
    [J]. EMBO MOLECULAR MEDICINE, 2010, 2 (07) : 247 - 257